Drug Trial Radar · NCT03768063
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Feb 28, 2019
Primary completion
Jul 5, 2028
Study completion Jul 5, 2028
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.
Conditions
- Cancer
Interventions
AtezolizumabDrug
Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
BevacizumabDrug
Bevacizumab will be administered as directed per the parent study.
AlectinibDrug
Alectinib will be administered as directed per the parent study.
CobimetinibDrug
Cobimetinib will be administered as directed per the parent study.
VemurafenibDrug
Vemurafenib will be administered as directed per the parent study.
FAP IL2VDrug
FAP IL2V will be administered as directed per the parent study.
VenetoclaxDrug
Venetoclax will be administered as directed per the parent study.
EnzalutamideDrug
Enzalutamide will be administered as directed per the parent study.
PembrolizumabDrug
Pembrolizumab will be administered as directed per the parent study.
SunitinibDrug
Sunitinib will be administered as directed per the parent study.
NiraparibDrug
Niraparib will be administered as directed per the parent study.
CabozantinibDrug
Cabozantinib will be administered as directed per the parent study.
PemetrexedDrug
Pemetrexed will be administered as directed per the parent study.
PaclitaxelDrug
Paclitaxel will be administered as directed per the parent study.
EmactuzumabDrug
Emactuzumab will be administered as directed per the parent study.
RucaparibDrug
Rucaparib will be administered as directed per the parent study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s)Time frame: Day 1 up to maximum 10 years
Locations
80 sites in 24 countries. Site status is shown where the registry gives one.
University of Colorado Cancer Center
Aurora, Colorado
Yale University School Of Medicine
Trumbull, Connecticut
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Carolina BioOncology Institute, PLCC
Huntersville, North Carolina
St. Luke's Cancer Care Associates
Bethlehem, Pennsylvania
University of Texas Health Sciences Center in San Antonio
San Antonio, Texas
St Vincent'S Hospital
Darlinghurst, New South Wales, Australia
Institut Jules Bordet
Brussels, Belgium
UZ Brussel
Brussels, Belgium
UZ Leuven
Leuven, Flemish Brabant, Belgium
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Multiprofile Hospital for Active Treatment Central Onco Hospital OOD
Plovdiv, Bulgaria
Pontificia Universidad Catolica de Chile
Santiago, Chile
Masaryk?v onkologický ústav
Brno, Czechia
Rigshospitalet
København Ø, Denmark
Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez
Lille, France
hopital de la Timone
Marseille, France
Institut Gustave Roussy
Villejuif, Île-de-France Region, France
CHU Angers
Angers, Pays de la Loire Region, France
Centre Antoine Lacassagne
Nice, Provence-Alpes-Côte d'Azur Region, France
Kliniken Essen-Mitte
Essen, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Asklepios-Fachklinik Muenchen-Gauting
Gauting, Germany
SRH Wald-Klinikum Gera
Gera, Germany
Lungenfachklinik Immenhausen
Immenhausen, Germany
Universitaetsklinikum Muenster
Münster, Germany
Universitaets-Hautklinik Tuebingen
Tübingen, Germany
Universitaettsklinikum Tübingen
Tübingen, Germany
Universitätsklinik Tübingen
Tübingen, Germany
Universitätsklinikum Ulm
Ulm, Baden-Wurttemberg, Germany
Krankenhaus Barmherzige Bruder Regensburg
Regensburg, Bavaria, Germany
Universitätsklinikum Schleswig-Holstein;Campus Lübeck
Lübeck, Schleswig-Holstein, Germany
Laiko General Hospital Athen
Athens, Greece
Anticancer Hospital Ag. Savas
Athens, Greece
Metropolitan Hospital
Piraeus, Attica, Greece
Grupo Angeles
Guatemala City, Guatemala
Queen Mary Hospital
Hong Kong, Hong Kong
Szegedi Tudományegyetem
Szeged, Hungary
Istituto Nazionale dei Tumori
Milan, Lombardy, Italy
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.